At 4-8 mg, single oral dose, healthy adult, WBTB protocol (lucid dreaming):

• Onset 30-60 min; peak 1-2 hr.
• Subjective dream intensification: dreams become more vivid, longer, more complex, more memorable. Sense of "being awake within the dream" increases — the marker of lucidity.
• ~40-50% of WBTB-protocol users on 8 mg report at least one clearly lucid dream that night.
• Common side effects: mild nausea (worse on empty stomach), occasional delayed sleep onset on the post-WBTB return-to-sleep.
• Hangover: most users report no morning hangover; some report mild residual GI upset or "groggy" feeling.

At 8-16 mg, healthy adult, daytime use (off-label nootropic):

• Onset 1-2 hr; peak 2-4 hr.
• Effect is subtle. Some users describe mild attentional sharpness, easier sustained focus, slight working-memory lift.
• More users report side effects than benefits at this dose range — nausea, mild sweating, mild bradycardia, GI hypermotility.
• Distinct from huperzine A: less "dirty" feel (huperzine sometimes produces irritability), more "balanced" cholinergic activation due to the nAChR PAM action smoothing the AChEI spike.

At 16-24 mg/day, chronic, AD population:

• Acute "feel" dampens within 1-2 weeks of titration. Therapeutic effect is slowing of cognitive decline, not subjective enhancement.
• Side effects (N/V/D, weight loss, sleep disruption) are most pronounced during titration; ~60-70% of patients tolerate the maintenance dose.
• Vivid dreams are common (cholinergic REM activation), sometimes nightmares.

Variability factors:

• CYP2D6 status — major metabolizer; PMs (~7-10% of Caucasians) have higher exposure → more side effects.
• Diet — taking with food significantly reduces nausea.
• Pre-existing GI conditions — IBS / sensitive stomach → much higher side effect risk.

• AChE inhibition tolerance: modest; chronic dosing produces some upregulation of AChE expression, partially offsetting the inhibition. Not a major clinical issue at therapeutic doses.
• α7 nAChR desensitization is REAL — the same pharmacology that makes galantamine interesting (allosteric potentiation) also produces receptor desensitization with chronic high-dose exposure. This is part of why daily nootropic use of galantamine is unattractive — the unique mechanism (the α7 PAM action) blunts itself fastest.
• Lucid-dream tolerance: anecdotally, 2-3 consecutive nights of galantamine WBTB drops the lucidity rate substantially. Lucid-dreaming protocols universally recommend ≥3-7 days between doses.
• Recommended cycle for nootropic (off-label) use: if attempted, 5 days on / 2 days off, or 2-3 weeks on / 1-2 weeks off. For the user: cycle is moot — recommendation is not to use chronically.
• Reset protocol: 2-4 weeks off restores α7 nAChR sensitivity. AChE expression normalizes within 1-2 weeks of discontinuation.

Synergistic with

• citicoline (the user's V stack): ✅ The Kennedy-pathway choline + cytidine substrate provides what galantamine's APL action sensitizes the receptors to. Mechanistically the cleanest pairing. However: this is also the pairing that makes chronic daily galantamine multiplicatively cholinergic — which is why a user in this archetype should not run galantamine chronically alongside citicoline. PRN-only.
• alpha-GPC (PRN): ✅ Stronger acute choline elevation than citicoline; the lucid-dream community stacks alpha-GPC 300-600 mg with galantamine 4-8 mg WBTB. Best pairing for the lucid-dream use case specifically.
• alcar (V5 plan): ✅ Acetyl group substrate for ChAT; potentiates the cholinergic loading. Mechanism-additive.
• modafinil (V5 plan): ⚠️ Modafinil increases ACh demand cortically; galantamine extends ACh tone. Theoretically synergistic for sustained cognitive performance, but the side effect stack (modafinil's mild HR/BP increase + galantamine's bradycardia + GI upset) makes this unappealing as a regular combination.

Avoid stacking with

• Other AChE inhibitors (donepezil, rivastigmine, huperzine A): ❌ Additive AChE inhibition → cholinergic excess (severe nausea, bradycardia, sweating, possibly cholinergic crisis). Standard contraindication.
• Anticholinergic drugs (oxybutynin, tricyclic antidepressants like amitriptyline, first-gen antihistamines like diphenhydramine, scopolamine): ❌ Mechanism-opposing. Galantamine's effect is blunted; the anticholinergic's effect may also be partially countered. Net: both drugs work worse.
• Succinylcholine (depolarizing neuromuscular blocker used in surgery): ❌ Galantamine-like AChEIs prolong succinylcholine action via butyrylcholinesterase inhibition. Surgical-anesthesia warning — disclose galantamine use before any surgery.
• Bradycardia-inducing drugs (beta-blockers, non-DHP calcium channel blockers, digoxin, amiodarone): ⚠️ Additive bradycardia / heart-block risk. Relevant if the user ever goes on propranolol PRN — galantamine PRN is fine if not the same day.
• NSAIDs (chronic, high dose): ⚠️ Galantamine increases gastric acid secretion via vagal stimulation; concurrent chronic NSAID use mildly elevates GI bleeding risk.
• Stacking 2+ choline donors + galantamine: ❌ At a chronic level (citicoline + alpha-GPC + galantamine), cholinergic over-tone is a real risk → flat affect, GI symptoms, bradycardia, sleep disruption. PRN single-event use is fine.

Neutral / safe co-administration

• the user's V stack stack items (NAC, magnesium glycinate/threonate, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, fish oil, creatine) — no significant interaction.
• Bromantane, Selank, Adamax/Semax (V5 peptides) — no documented interaction.
• Caffeine — mildly opposing on HR (caffeine increases, galantamine decreases) but not problematic at typical doses.

• CYP2D6 — major metabolic pathway. CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) increase galantamine exposure by 25-50%. Bupropion is in the user's V stack optional list — relevant interaction if both are used.
• CYP3A4 — secondary metabolic pathway. Strong CYP3A4 inhibitors (ketoconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice in large quantities) increase galantamine exposure by 20-40%.
• CYP2D6 + CYP3A4 dual inhibition (e.g., paroxetine + ketoconazole) → galantamine AUC up to 2× higher → side effects multiplied.
• CYP inducers (rifampin, carbamazepine, phenytoin, St. John's wort) — decrease galantamine exposure, may reduce efficacy.
• Renal/hepatic impairment — moderate hepatic impairment requires dose reduction; severe hepatic or renal impairment is a relative contraindication.
• No CYP enzyme induction or inhibition by galantamine itself — it doesn't significantly affect the metabolism of other drugs.
• Hormonal contraceptives: no documented interaction.
• Alcohol: no specific interaction; both are cholinergic-modulating in opposing directions in different brain regions, but no clinical interaction signal.
• Anesthesia (succinylcholine): see Stacking section above. Disclose to anesthesiologist.

• CYP2D6: the dominant PGx variable. Poor metabolizers (PMs, ~7-10% of European-ancestry populations, ~1-5% Asian, ~1-3% African; the user's Nordic/British ancestry → ~7-10% prior) have ~25-50% higher galantamine AUC and 5-fold higher peak concentrations of galantamine metabolites. Practical effect: PMs experience meaningfully more nausea, GI upset, bradycardia at standard doses. Ultra-rapid metabolizers (UMs, ~3-5% Caucasians) have lower exposure and may need slightly higher doses for AD efficacy.
• CYP3A4 variants are less impactful but additive with CYP2D6.
• APOE ε4 — carriers have earlier and more pronounced cholinergic deficit in AD. Multiple studies suggest AChEIs work better in ε4 carriers (some studies show ε4+ patients respond more robustly to galantamine/donepezil). Relevant for users in this archetype post-23andMe (June 2026) — if ε4+, the broader cholinergic-stack rationale becomes stronger (citicoline already covers; galantamine still WATCH-LIST but slightly more interesting).
• CHRNA7 / CHRFAM7A (α7 nAChR gene variants): theoretical modulators of galantamine's APL response. Limited clinical data.
• BCHE (butyrylcholinesterase) variants: some 2024 work suggests BCHE-K carriers respond differently to AChEIs; rivastigmine more affected than galantamine.
• Action for users in this archetype: When 23andMe results land (~June 5-15, 2026), check CYP2D6 metabolizer status. If PM → galantamine even less attractive (more side effects at any dose). Check APOE — ε4+ slightly raises galantamine's strategic value for chronic cognitive preservation, though still not enough to outweigh α7 desensitization issue for daily use.

Recommendation for users in this archetype IF pursuing lucid dreaming PRN (the only relevant use case): Doublewood Galantamine 4 mg × 60 caps (Amazon, ~$20). Two caps = 8 mg WBTB dose. ~30 doses per bottle = 1-2 years of monthly use. Pair with existing citicoline 500 mg or PRN alpha-GPC 300-600 mg.

Recommendation if NOT pursuing lucid dreaming: don't source. No daily-use case justifies the regulatory + side-effect burden over the user's existing cholinergic coverage (citicoline V4, alpha-GPC PRN as planned).

Baseline (before starting any chronic use; not needed for PRN lucid-dreaming)

• Resting heart rate (galantamine causes mild bradycardia; baseline matters for athletes with already-low HR).
• Blood pressure (rule out symptomatic hypotension risk).
• Weight (chronic galantamine AD use is associated with 2-3 kg weight loss; meaningful for an athlete needing to maintain training weight).
• Liver panel (ALT, AST, GGT, alk phos) — galantamine is hepatically cleared; baseline before chronic use.
• CBC, CMP — general baseline.
• Optional: ECG if any cardiac history or family history of conduction abnormality.

During use (chronic only, not PRN)

• HR + BP weekly during titration, then monthly.
• Weight monthly.
• GI symptom tracking (nausea, bowel pattern) daily for first 4 weeks.
• Sleep architecture if available (Oura / WHOOP) — REM% changes are the marker of cholinergic effect on sleep.
• Subjective cognition — daily score during titration.

Post-cycle (if cycled or discontinued)

• 2-4 week washout restores α7 nAChR sensitivity. AChE expression normalizes within 1-2 weeks.